CP and pneumococcal infection: (b) Cp 090104 and CP-derived BLPs enhance the adaptive immune responses induced by pneumococcal vaccines and boost resistance to primary pneumococcal infection. Our previous research showed that nasal priming with Cp 090104 and CP-derived BLPs enhances the effectiveness of the pneumococcal conjugate vaccine Prevenar®13 (PCV) by acting as mucosal adjuvants [13].